EMERGENT BIOSOLUTIONS INC. (NYSE:EBS) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement.
wholly-owned subsidiary of Emergent BioSolutions Inc., entered
into a contract with the Biomedical Advanced Research and
Development Authority (BARDA), a division within the Office of
the Assistant Secretary of Preparedness and Response, valued at
$100 million for the delivery of BioThrax (Anthrax Vaccine
Adsorbed) to the Strategic National Stockpile over a two-year
period of performance.
customary for government contracts of this nature, including
provisions giving the government the right to terminate the
contract at any time for its convenience for any reason or no
reason, to order the company to suspend all or any part of the
work under the contract at the government’s discretion or to
audit and object to any contract-related costs on the grounds
that they are not allowable under the Federal Acquisition
Regulation and require the company to reimburse all such costs.
complete and is qualified in its entirety by reference to the
actual contract, a copy of which will be filed as an exhibit to
the company’s Quarterly Report on Form 10-Q for the quarterly
period ending March 31, 2017.
of NuThrax
Inc., a wholly-owned subsidiary of Emergent BioSolutions Inc.,
entered into a modification to its previously disclosed
multi-year contract with BARDA for the advanced development and
delivery of NuThraxTM (anthrax vaccine adsorbed
with CPG 7909 adjuvant). The modification increases the number of
doses of NuThrax to be delivered under the base period from two
million to three million doses with a commensurate reduction in
dose price for the initial deliveries. The modification also
reduces the purchase price for doses to be procured during the
option period by $100 million thereby reducing the total contract
value to be up to $1.5 billion, from the previously disclosed
$1.6 billion.
complete and is qualified in its entirety by reference to the
actual modification, a copy of which will be filed as an exhibit
to the company’s Quarterly Report on Form 10-Q for the quarterly
period ending March 31, 2017.
|
Exhibit No.
|
Description
|
|
|
Press Release dated March 17, 2016.
|
About EMERGENT BIOSOLUTIONS INC. (NYSE:EBS)
Emergent BioSolutions Inc. is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company develops, manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID). It also develops and commercializes therapeutics in areas of hematology/oncology, transplantation, infectious diseases and autoimmune disorders. Its two operating divisions include Biodefense and Biosciences. The Biodefense division is a pharmaceutical business focused on countermeasures that address public health threats, including chemical, biological, radiological, nuclear and explosives (CBRNE) threats, as well as EID. The Biosciences division is a pharmaceutical business focused on therapeutics in hematology/oncology with secondary on transplantation, infectious disease and autoimmunity. EMERGENT BIOSOLUTIONS INC. (NYSE:EBS) Recent Trading Information
EMERGENT BIOSOLUTIONS INC. (NYSE:EBS) closed its last trading session down -0.13 at 30.76 with 318,374 shares trading hands.
